Home › NCT04107285
Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy
RecruitingObservational study
A Study of Longitudinal Neurocognitive and Neuroimaging Evaluations for Adult Patients With Lymphoma Receiving CD19 CAR T Cell Therapy
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients must be 18 years of age or older * Planned treatment with commercial CD19-specific CAR T cells (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, or brexacabtagene autoleucel) for lymphoma. * Patients must have adequate end organ function for CAR T cell therapy * Eastern Cooperative Group (ECOG) performance status of 0 to 2 * Meet cardiac, pulmonary, hematologic, hepatic, and renal requirements for CART therapy as described in corresponding product package insert * No evidence of central nervous system disease at study entry * Fluent and able to communicate well enough in English to complete the study assessments and provide informed consent, in the judgment of the consenting professional. o Patients who report that English is not their primary language will be asked the US Census English proficiency question: "How well do you speak English," and the answer "very well" will be required Exclusion Criteria: * Signs and/or symptoms of central nervous system cancer (e.g., metastases, leptomeningeal disease) as determined by their physician, medical records, or by a brain MRI, either at the time of enrollment or during the study period. * Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report * History of neurodegenerative disease, or traumatic brain injury with loss of consciousness (\>60 minutes), as per medical records or patient report * A history of epilepsy as per medical records or patient report * Current ongoing substance abuse and/or history of substance abuse, as per medical records or patient report * Evidence of visual or auditory impairment that would preclude completion of the assessments, as per medical records or patient report * Contraindications to MRI examinations as per standard screening guidelines used in the Department of Radiology (i.e., ferromagnetic material or implants, pacemakers or defibrillators, stents, claustrophobia)
About the study
The purpose of this study is to learn about possible changes in cognitive (mental) abilities, such as memory skills and concentration, and in brain anatomy (structure) and function, in people with lymphoma receiving CAR-T therapy.
What is being tested
- neurocognitive evaluations (behavioral)
- brain MRIs (diagnostic test)
- Blood samples (other)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 120 · Started: Sep 25, 2019
Contact the study team
- Bianca Santomasso, MD, PhD · Phone: 646-888-2092
- Denise Correa, PhD · Phone: 212-610-0487
Official record on ClinicalTrials.gov — NCT04107285
Locations in the U.S.
| New York | Memorial Sloan Kettering Cancer Center, New York |
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.